255 related articles for article (PubMed ID: 35242129)
1. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4
Hadjis AD; Nunes NS; Khan SM; Fletcher RE; Pohl AP; Venzon DJ; Eckhaus MA; Kanakry CG
Front Immunol; 2022; 13():796349. PubMed ID: 35242129
[TBL] [Abstract][Full Text] [Related]
2. Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation.
Wachsmuth LP; Patterson MT; Eckhaus MA; Venzon DJ; Kanakry CG
Biol Blood Marrow Transplant; 2020 Feb; 26(2):230-241. PubMed ID: 31586477
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
Nunes NS; Kanakry CG
Front Immunol; 2019; 10():2668. PubMed ID: 31849930
[TBL] [Abstract][Full Text] [Related]
4. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.
Wachsmuth LP; Patterson MT; Eckhaus MA; Venzon DJ; Gress RE; Kanakry CG
J Clin Invest; 2019 Mar; 129(6):2357-2373. PubMed ID: 30913039
[TBL] [Abstract][Full Text] [Related]
5. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.
Ganguly S; Ross DB; Panoskaltsis-Mortari A; Kanakry CG; Blazar BR; Levy RB; Luznik L
Blood; 2014 Sep; 124(13):2131-41. PubMed ID: 25139358
[TBL] [Abstract][Full Text] [Related]
6. Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects.
Patterson MT; Khan SM; Nunes NS; Fletcher RE; Bian J; Hadjis AD; Eckhaus MA; Mendu SK; de Paula Pohl A; Venzon DJ; Choo-Wosoba H; Ishii K; Qin H; Fry TJ; Cam M; Kanakry CG
Blood; 2023 Feb; 141(6):659-672. PubMed ID: 36201744
[TBL] [Abstract][Full Text] [Related]
7. Increased Infections and Delayed CD4
Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
[TBL] [Abstract][Full Text] [Related]
8. Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.
Nakamae H
Int J Hematol; 2022 Oct; 116(4):465-481. PubMed ID: 35930118
[TBL] [Abstract][Full Text] [Related]
9. Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs.
Fletcher RE; Nunes NS; Patterson MT; Vinod N; Khan SM; Mendu SK; Li X; de Paula Pohl A; Wachsmuth LP; Choo-Wosoba H; Eckhaus MA; Venzon DJ; Kanakry CG
Blood Adv; 2023 Apr; 7(7):1117-1129. PubMed ID: 36595377
[TBL] [Abstract][Full Text] [Related]
10. Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.
Makuuchi Y; Nakashima Y; Nishimoto M; Koh H; Hino M; Nakamae H
Exp Hematol; 2023 Jul; 123():56-65. PubMed ID: 37098360
[TBL] [Abstract][Full Text] [Related]
11. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
[TBL] [Abstract][Full Text] [Related]
12. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
[TBL] [Abstract][Full Text] [Related]
13. [Current state of graft-versus-host disease prophylaxis with PTCy for allogeneic hematopoietic stem cell transplantation].
Nakamae H
Rinsho Ketsueki; 2024; 65(5):391-400. PubMed ID: 38825519
[TBL] [Abstract][Full Text] [Related]
14. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
[TBL] [Abstract][Full Text] [Related]
15. Commentary: Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation.
Stokes J; Simpson RJ; Katsanis E
Front Immunol; 2022; 13():887648. PubMed ID: 35493453
[No Abstract] [Full Text] [Related]
16. Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis.
Oshrine B; Innamarato P; Branthoover H; Nagle L; Verdugo P; Pilon-Thomas S; Beatty M
Transplant Cell Ther; 2022 Apr; 28(4):203.e1-203.e7. PubMed ID: 34995816
[TBL] [Abstract][Full Text] [Related]
17. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.
Adhikary SR; Cuthbertson P; Nicholson L; Bird KM; Sligar C; Hu M; O'Connell PJ; Sluyter R; Alexander SI; Watson D
Immunology; 2021 Oct; 164(2):332-347. PubMed ID: 34021907
[TBL] [Abstract][Full Text] [Related]
19. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
20. Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice.
Cuthbertson P; Button A; Sligar C; Elhage A; Vine KL; Watson D; Sluyter R
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
